Shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) shot up 9.1% on Thursday . The stock traded as high as $0.45 and last traded at $0.40. 589,529 shares traded hands during mid-day trading, a decline of 27% from the average session volume of 809,710 shares. The stock had previously closed at $0.44.
Several brokerages recently weighed in on SYN. BidaskClub lowered Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Zacks Investment Research lowered Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Thursday, January 11th.
The firm has a market cap of $56.58, a price-to-earnings ratio of -2.00 and a beta of 1.08.
ILLEGAL ACTIVITY NOTICE: “Synthetic Biologics (SYN) Shares Up -9.1%” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/synthetic-biologics-syn-shares-up-9-1.html.
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.